These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 30838648)

  • 1. Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder.
    Isharwal S; Hu W; Sarungbam J; Chen YB; Gopalan A; Fine SW; Tickoo SK; Sirintrapun SJ; Jadallah S; Loo FL; Pietzak EJ; Cha EK; Bochner BH; Berger MF; Iyer G; Solit DB; Reuter VE; Al-Ahmadie H
    J Pathol; 2019 Jul; 248(3):260-265. PubMed ID: 30838648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RAS Family Gene Mutations, Clinicopathological Features, and Spread Patterns of Inverted Urothelial Papilloma of the Bladder.
    Kitahama K; Shigematsu Y; Amori G; Sugawara E; Yonese J; Shibahara J; Takeuchi K; Inamura K
    Am J Surg Pathol; 2024 Apr; 48(4):458-464. PubMed ID: 38145408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential.
    Wang CC; Huang CY; Jhuang YL; Chen CC; Jeng YM
    Histopathology; 2018 Apr; 72(5):795-803. PubMed ID: 29193225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HRAS mutations are frequent in inverted urothelial neoplasms.
    McDaniel AS; Zhai Y; Cho KR; Dhanasekaran SM; Montgomery JS; Palapattu G; Siddiqui J; Morgan T; Alva A; Weizer A; Lee CT; Chinnaiyan AM; Quist MJ; Grasso CS; Tomlins SA; Mehra R
    Hum Pathol; 2014 Sep; 45(9):1957-65. PubMed ID: 25097040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change.
    Cheng L; Davidson DD; Wang M; Lopez-Beltran A; Montironi R; Wang L; Tan PH; MacLennan GT; Williamson SR; Zhang S
    Histopathology; 2016 Jul; 69(1):107-13. PubMed ID: 26679899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct mutational landscape of inverted urothelial papilloma.
    Akgul M; MacLennan GT; Cheng L
    J Pathol; 2019 Sep; 249(1):3-5. PubMed ID: 31119740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma.
    Eich ML; Rodriguez Pena MDC; Springer SU; Taheri D; Tregnago AC; Salles DC; Bezerra SM; Cunha IW; Fujita K; Ertoy D; Bivalacqua TJ; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Netto GJ
    Mod Pathol; 2019 Oct; 32(10):1544-1550. PubMed ID: 31028363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Urothelial hyperplastic lesion with endophytic growth pattern: a clinicopathologic study].
    Xiao L; Wang CF; Zhu XZ; Yin YL; Chen Y; Lu C; Yu B
    Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):319-23. PubMed ID: 21756826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
    Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M
    Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical and morphological features of a non-invasive papillary urothelial carcinoma, evolving from a urothelial inverted papilloma of the bladder].
    Pascal A; Dobromir N; Ivan L
    Rev Med Chir Soc Med Nat Iasi; 2009; 113(1):150-3. PubMed ID: 21495311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Significance of TERT promoter mutation in differential diagnosis of non-invasive inverted urothelial lesions of bladder].
    Zhang YH; Xie JJ; Wang JG; Wang Y; Zhan XH; Gao J; He HY
    Zhonghua Bing Li Xue Za Zhi; 2023 Dec; 52(12):1216-1222. PubMed ID: 38058037
    [No Abstract]   [Full Text] [Related]  

  • 13. Inverted urothelial papilloma: is ploidy, MIB-1 proliferative activity, or p53 protein accumulation predictive of urothelial carcinoma?
    Cheville JC; Wu K; Sebo TJ; Cheng L; Riehle D; Lohse CM; Shane V
    Cancer; 2000 Feb; 88(3):632-6. PubMed ID: 10649258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inverted Papilloma of the Bladder Coexisting with Urothelial Carcinoma. A Case Report.
    Veiga RS; Cassis J; Oliveira P; Lopez-Beltran A
    Anal Quant Cytopathol Histpathol; 2016 Feb; 38(1):52-6. PubMed ID: 27363067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inverted papilloma of the bladder: a review and an analysis of the recent literature of 365 patients.
    Picozzi S; Casellato S; Bozzini G; Ratti D; Macchi A; Rubino B; Pace G; Carmignani L
    Urol Oncol; 2013 Nov; 31(8):1584-90. PubMed ID: 22520573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent FGFR3 mutations in urothelial papilloma.
    van Rhijn BW; Montironi R; Zwarthoff EC; Jöbsis AC; van der Kwast TH
    J Pathol; 2002 Oct; 198(2):245-51. PubMed ID: 12237885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inverted urothelial papilloma of the urinary bladder with focal papillary pattern: a previously undescribed feature.
    Albores-Saavedra J; Chable-Montero F; Hernández-Rodríguez OX; Montante-Montes de Oca D; Angeles-Angeles A
    Ann Diagn Pathol; 2009 Jun; 13(3):158-61. PubMed ID: 19433293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma.
    Nguyen D; Taheri D; Springer S; Cowan M; Guner G; Mendoza Rodriguez MA; Wang Y; Kinde I; VandenBussche CJ; Olson MT; Ricardo BF; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
    Virchows Arch; 2016 Oct; 469(4):427-34. PubMed ID: 27520411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spectrum of genetic mutations in de novo PUNLMP of the urinary bladder.
    Rodriguez Pena MDC; Tregnago AC; Eich ML; Springer S; Wang Y; Taheri D; Ertoy D; Fujita K; Bezerra SM; Cunha IW; Raspollini MR; Yu L; Bivalacqua TJ; Papadopoulos N; Kinzler KW; Vogelstein B; Netto GJ
    Virchows Arch; 2017 Dec; 471(6):761-767. PubMed ID: 28597078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
    Moss TJ; Qi Y; Xi L; Peng B; Kim TB; Ezzedine NE; Mosqueda ME; Guo CC; Czerniak BA; Ittmann M; Wheeler DA; Lerner SP; Matin SF
    Eur Urol; 2017 Oct; 72(4):641-649. PubMed ID: 28601352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.